Alnasrallah B, et al. - Researchers evaluated metformin for its feasibility, tolerability and effectiveness following renal transplantation in patients with impaired glucose tolerance in a single-center, unblinded, pilot randomized controlled trial (Transdiab). They randomized 19 participants to standard care or standard care and metformin 500 mg twice daily. Participants were then observed for 12 months. Both groups demonstrated comparable tolerability and effectiveness and no serious adverse events were seen. The secondary outcomes relating to the metabolic profile were also not different. According to the findings, metformin use after kidney transplantation appeared feasible and safe.